Navigation Links
Affitech Appoints Dr. Keith McCullagh as Chairman
Date:9/9/2008

OSLO, Norway, September 9 /PRNewswire/ -- Affitech AS, the Norwegian antibody therapeutics company, today announced that it has appointed Dr Keith McCullagh as non-executive Chairman of its Board of Directors. The Company's previous chairman, Oyvin Broymer, will remain as a member of the Board. Mr Broymer welcomed Dr McCullagh's appointment and said:

"I am delighted that Keith McCullagh has agreed to take over from me as Affitech's new chairman. He has an outstanding entrepreneurial track record in the biopharmaceutical industry, most recently at Santaris Pharma in Denmark, where as CE0 he has played a major role in establishing the company as a leader in the RNA medicines field. Affitech's antibody technology is in a different area of the biopharmaceuticals market, but I am confident that Affitech will benefit from his leadership and guidance. I wish him every success."

Accepting the appointment, Keith McCullagh commented:

"Affitech has significant potential in the field of human monoclonal antibody therapeutics. Both its cell-based and target antigen screening technology is at the forefront of the industry and I look forward to assisting the Company's management, board and shareholders to build the resources and competencies required to develop innovative potential new products. I look forward to Affitech achieving several competitive commercial goals in the coming years."

Affitech intends to focus its future development on building a pipeline of proprietary therapeutic antibody product candidates, through both in-house research and development and alliances with other companies.

Affitech CEO, Dr Martin Welschof, commented:

"I thank Oyvin Broymer, who took over the chairmanship of Affitech in 2002 at a time of major strategic change and has skillfully guided us to our current position. I look forward to working closely with Keith McCullagh, whose experience in building successful biotech companies will be of great v
'/>"/>

SOURCE Affitech AS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... In Total Revenue To $5.6 Million; 34% Increase in ... International Isotopes Inc. (OTC Bulletin Board: INIS) announces ... 2008. Total Revenue . Total ... 2007, which represents an increase of $911,885 or 19.4%. ...
... 27 Human Genome Sciences, Inc. (Nasdaq: ... at the 4th Annual Citi Biotech Day will be ... . (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ... team will present a corporate overview on Wednesday, April ...
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ... develops and commercializes prescription drugs for the treatment ... the fourth quarter and year ended December 31, ... J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical ...
Cached Biology Technology:International Isotopes Inc. Announces Year End Financial Results 2International Isotopes Inc. Announces Year End Financial Results 3International Isotopes Inc. Announces Year End Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 2Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 3Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 5Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 6
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... epic 354-million-mile trek through space, the Mars Curiosity Rover ... a scheduled August 6 landing on the Red Planet ... episode of the American Chemical Society,s (ACS,) award-winning ... scientific instrumentation and the role that chemistry plays in ...
... stress, a new research report appearing in the August 2012 ... suggests that what your mother ateor didn,t eatmay be part ... is higher than what is generally recommended during pregnancy may ... the result of epigenetic changes that ultimately lead to lower ...
... a smog-filled sky or a contaminated river, according to ... just for the prosperous. People living in China,s ... are more likely to begreen: re-using their plastic grocery ... in the international journal AMBIO , indicates that ...
Cached Biology News:Sick from stress? Blame your mom… and epigenetics 2Pollution can make citizens - both rich and poor - go green 2
... Mung Bean Nuclease catalyzes the degradation of ... 5-phosphoryl terminated products. While the nuclease prefers ... high concentrations the enzyme degrades double-stranded DNA ... has been used for transcript mapping studies ...
... The S.c. EasyComp Transformation Kit ... transformation-competent Saccharomyces cerevisiae cells. Advantages over ... spheroplast formation or LiCl methods include:- Cells ... than 30 minutes - Competent cell preparation ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
Biology Products: